Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089101 | 0.89 | KDM4E (0.46) | KDM4ELMNAGFERKMT2AGAA | |
| SCHEMBL30941590 | 0.81 | USP30 (0.56) | GFERKMT2A | |
| SCHEMBL29136112 | 0.81 | USP30 (0.56) | GFERKMT2A | |
| SCHEMBL18613893 | 0.81 | KDM4E (0.49) | KDM4ELMNAKMT2A | |
| SCHEMBL27177207 | 0.79 | KMT2A (0.50) | GFERKMT2AGAA | |
| SCHEMBL29136105 | 0.79 | KMT2A (0.50) | GFERKMT2AGAA | |
| SCHEMBL30088942 | 0.79 | HRH1 (0.48) | KDM4EGFER | |
| SCHEMBL31554320 | 0.76 | USP30 (0.43) | SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL30089100 | 0.76 | JAK3 (0.44) | GFERPOLB | |
| SCHEMBL30089039 | 0.75 | POLB (0.48) | SMN1; SMN2KDM4ELMNAKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4341252-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. Hoffmann-La Roche AG (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2022243346-A1 | OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2022-11-24 | — | — | WO | disclosed |